|
|
|
Issue Open Date
|
25-Sep-17
|
|
|
|
Issue Closing Date
|
27-Sep-17
|
|
|
|
Application Money
|
100
|
|
|
|
Allotment Money
|
|
|
|
|
|
|
|
Price Band
|
50
-
|
|
|
|
Minimium Application No.
|
3000
|
|
|
|
Issue Size (Shares)
|
1512000
|
|
|
|
Market Lot
|
1
|
|
|
|
|
|
Objective
|
|
The objects of the Net Proceeds (as defined below) of the Issue are:1. Augmenting additional working capital requirements2. General Corporate Purposes
|
|
|
|
|
|
|
Category
|
No. of Shares
|
No. of Shares
|
Subscription Ratio
|
|
|
Offered / Reserved |
Bid For |
|
|
Non-Institutional Investors
|
|
|
|
|
Qualified Institutional Buyers
|
|
|
|
|
Retail Individual Investors
|
|
|
|
|
|
|
|
Business Description
OverviewVanta Bioscience Limited (VBS) is a preclinical contract research organization, offering a host of preclinical safetyassessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech,Agrochemicals, Cosmetics, and Chemical industries. In addition we also provide risk assessment services for evaluatingthe safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables includingpharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. VBS alsoprovides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) orallowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers.We entered into an asset transfer agreement dated February 18, 2016 with Kemin Industries South Asia Private Limited,Chennai for the purchase of fully operational toxicology facility =Vanta Bioscience‘ situated at Plot K2B, SIPCOTIndustrial Estate, Gummidipundi, Chennai 601 201. The purchase include the entire facility including the land &buildings, equipments, materials, spares, laboratory animals to be used in preclinical research and other inventoriesincluding all licenses, permits, approvals, registrations, accreditations, IPRs, SOPs and existing manpower. Theconsideration for the aforementioned purchase is Rs. 1,200 lakhs. Our Company has taken possession of the saidpreclinical CRO facility at Gummidipundi, Chennai and has commenced commercial operations thereat from April 1,2017. Currently we are mainly doing previous pending research work and are also getting new work from existing clientsof ?Vanta Bioscience? erstwhile division of Kemin Industries South Asia Private Limited. In addition to this we are innegotiation with few clients in Agro Chemical, Pharmaceutical and Food Industry.One of the major services of VBS is conducting variety of in vitro (cell, tissue and organisms) and in vivo (animal)toxicology studies for its diverse clients as per various regulatory requirements from across the world. Toxicology is abranch of biology, chemistry, and pharmacology concerned with the study of the adverse effects of chemicals on livingorganisms. It also studies the harmful effects of chemical, biological and physical agents in biological systems thatestablish the extent of damage in living organisms. The relationship between dose and its effects on the exposedorganism is of high significance in toxicology. Toxicology and safety assessment are sometimes used interchangeablyand considered as synonymous.VBS has state of the art facilities and infrastructure necessary for conduct of all kind of toxicology studies for Chemicals,Pharmaceuticals, Cosmetics, Agrochemicals like Pesticides, Insecticides, Excipients, Novel Feed Additives The datagenerated from these studies are submitted to regulatory agencies worldwide before they are put in use for theconsumption of domestic animals and human being. In addition, VBS also conducts preclinical proof-of-concept (PoC)studies for novel pharmaceuticals and products intended for new indications in variety of animal models of humandiseases through a robust process of validation.Pharmaceutical drug development is an expensive and lengthy process with high risk of failures in the late state ofclinical development. Toxicity is the most cited reason after efficacy for late stage failure of drugs. Therefore, there hasbeen a shift in the approach of pharmaceutical industry from traditional drug development process. This has led to a morefocused approach to identify and eliminate the drug candidates having potential to cause unacceptable toxicities andsafety issues at the early phase of drug discovery and development phase. This strategic shift in the drug developmentprocess created tremendous opportunities for preclinical contract research organization for collaboration withpharmaceutical industry for conduct of early discovery toxicology and pharmacology studies for identification of bettercandidate molecules for further development. VBS equipped with state of the art infrastructure, qualified and highlyexperienced scientists with thorough knowledge and understanding of pharmaceutical drug development process is wellpositioned for any future collaboration and partnership with pharmaceutical industry from India and abroad. Thisintegrated drug discovery and development model is emerging as symbiotic relationship for both the partners. VBS plansto leverage this opportunity on priority and integrate itself with global pharmaceutical industry for any futurecollaboration in this area as part of its strategic business plan.As per the agreement, Kemin Industries South Asia Private Limited has transferred all the rights and licences to use thecompany name ?Vanta Bioscience? as part of the name of new company.
|
|
|
Promoter's Holding
|
|
|
|
Total Share Capital
|
|
|
|
|
Offered to Public
|
|
|
|
|
Promoter's Holding (Pre-Issue)
|
|
|
|
|
Promoter's Holding (Post-Issue)
|
|
|
|
|
|
|
|
|
|
|
|
Address |
No.02/ G/308/ G
No.3/ F F/ S F/1-20-248
Umajay Complex
Rasoolpura
Secunderabad
Hyderabad,
Telangana,
500003
Phone : 040-6657 5454 / 2790 3226
Email : cs@vantabio.com / info@vantabio.com
Website : www.vantabio.com
|
|
|
Registrar |
Bigshare Services Pvt Ltd
G 10 Left Wing Amruta Village
Opp: Yashoda Hospital
Raj Bhavan Road
Somajiguda
Hyderabad
|
|
|
Listed at |
|
BSE
|
|
|
Lead Manager |
|
Inventure Merchant Bankers Services Pvt Ltd.
|
|
|
Promoters |
Chandrasekhar Rao Simhadri
Dopesh Raja Mulakala
Karishma Mulakala
Mohan Krishna Mulakala
Pradeep Chowdary
Sajan Kiran Mulakala
Shravan Chintapatla
Soumya Simhadri
Vyasmurti Madhavrao Shingatgeri
|
|
